Search Results for Fibrosis

NASH Observatory, Commented Articles

Sequential combination of NIS-4, MACK-3, and FAST scores

For Y. J. Zhou, et al., there is an urgent need to identify patients who are at risk of developing NASH. Traditional, non-invasive tests have been developed to identify either NASH or advanced fibrosis. However, these tests do not accurately detect patients who are at risk of NASH.
Harrison et al. developed and validated the NIS4 test that provides...

Dr. G. Bozet, MD
June 7, 2021

Pathophysiology

New insights into liver macrophages in NASH pathogenesis

Prof Tacke, Germany reviews the epidemiological challenge of NAFLD and NASH worldwide, especially with the obesity pandemic. He describes the clinical impact of inflammation and fibrosis in NAFLD and the role of macrophages. Finally, he discusses the possible therapeutic implications.

Prof. Frank Tacke
May 31, 2021

NASH Observatory, Commented Articles, Ppar Articles

PPARs as candidates for the treatment of NAFLD

The prevalence of NAFLD is dramatically increasing in developed countries, but no approved therapy is available. Most of the current pharmacological strategies target comorbidities, such as manifestations of metabolic syndrome. In addition, none of used medications improve fibrosis, which is the strongest indicator of mortality in NAFLD...

Dr. G. Bozet, MD
May 31, 2021

NASH Observatory, Commented Articles

NAFLD is significantly related to non-achievement of LDL cholesterol targets

To reduce cardiovascular disease (CVD) risk as much as possible, current guidelines recommend optimising LDL cholesterol management based on an individual’s CVD risk level. The risk of CVD among NAFLD patients is likely to be higher than it is in...

Dr. D. Beard
May 31, 2021

NASH Observatory, Commented Articles

OSA with NAFLD in patients with obesity: an observational study

A growing amount of evidence has correlated obstructive sleep apnea (OSA) with the presence of NAFLD and it has been demonstrated a direct association between the severity of the former and the progression of the latter. Thus, OSA patients should be screened for the presence and severity of NAFLD...

Dr. G. Bozet, MD
May 27, 2021

NASH Observatory, Commented Articles

Patients with biopsy proven NAFLD: a significantly increased cancer incidence

Recent studies link NAFLD to an increased incidence of hepatocellular carcinoma (HCC) and extrahepatic cancers. However, prior studies were small or lacked liver histology, which remains the gold standard for staging NAFLD severity. TG Simon et al...

Dr. D. Beard
May 27, 2021

NASH Observatory, Commented Articles, Epidemiology Articles

Adult US population: NAFLD prevalence 38%, NASH 14%

S. A. Harrison et al. (Radcliffe Department of Medicine, University of Oxford, UK) prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. Screening for NAFLD was performed using magnetic resonance...

Dr. G. Bozet, MD
May 17, 2021

Management Articles, Commented Articles, NASH Observatory, Ppar Articles

Management of NAFLD: a review

As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Anti-inflammatory, anti-fibrotic agents and metabolism modulators...

Dr. G. Bozet, MD
May 10, 2021

Comorbidities, Management

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.

Prof. Kenneth Cusi
May 4, 2021

NASH Observatory, Commented Articles, Pathophysiology Articles

From NASH to hepatocellular carcinoma

End-stage NAFLD with liver cancer has an abysmal prognosis and effective medical therapies are lacking, therefore a better understanding of the disease mechanisms will ultimately help to improve patients’ care. The pathogenesis of NAFLD and transition to HCC is multifactorial, yet inflammation is considered a key element...